DOI : 10.1055/s-00000094

Zeitschrift für Gastroenterologie

Issue 05 · Volume 56 · May 2018 DOI: 10.1055/s-008-39855

Österreichische Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH)
51. Jahrestagung & 29. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH)
Salzburg, 14.–16.06.2018

Kongresspräsidenten: Prim. Univ.-Prof. Dr. Christian Datz Prim. Univ.-Prof. Dr. Rainer Schöfl Kongresssekretäre: Assoc.-Prof. Dr. Elmar Aigner OA Dr. Alexander Ziachehabi Fortbildungskurs: Univ.-Prof. Dr. Peter Ferenci Prim. Univ.-Prof. Dr. Rainer Schöfl
Abstracts (HTML) List of Authors
P24
Schaefer, B; Finkenstedt, A; Viveiros, A; Tilg, H; Zoller, H: Ceruloplasmin knockout mice as a disease model for aceruloplasminemia
P25
Horvath, A; Rainer, F; Leber, B; Schmerböck, B; Spindelböck, W; Stauber, RE; Stiegler, P; Stadlbauer, V: AGRA – a functional biomarker for humoral immune function predicts the development of severe bacterial infections in cirrhosis
P26
Chromy, D; Mandorfer, M; Theresa, B; Schwabl, P; Scheiner, B; Schmidbauer, C; Aichelburg, M; Ferenci, P; Trauner, M; Peck-Radosavljevic, M; Reiberger, T: High efficacy of IFN-free DAA therapy for acute HCV infection in HIV patients
P27
Scheck, S; Rainer, F; Zollner, G: Drug-Induced Liver Injury (DILI) – Charakterisierung von 90 Fällen an der Medizinischen Universität Graz
P28
Fuchs, CD; Paumgartner, G; Wolfrum, S; Wahlström, A; Stahlman, M; Stojakovic, T; Wolfrum, C; Marschall, H; Trauner, M: Loss of BSEP/ABCB11 protects MDR2/ABCB4 KO mice from cholestatic liver injury by altering bile acid profile and signaling
P29
Unger, LW; Forstner, B; Schneglberger, S; Muckenhuber, M; Eigenbauer, E; Mandorfer, M; Gnant, M; Trauner, M; Reiberger, T: High prevalence of dyslipidemia but insufficient statin use in patients with non-cirrhotic and cirrhotic liver disease
P30
Grander, C; Schäfer, B; Grabherr, F; Enrich, B; Tilg, H: Alpha-1 antitrypsin administration ameliorates experimental acute alcoholic liver disease
P31
Golob-Schwarzl, N; Krassnig, S; Birkl-Toeglhofer, A; Park, Y; Gogg-Kamerer, M; Puchas, P; Vierlinger, K; Schröder, F; Schicho, R; Fickert, P; Haybäck, J: New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors
P32
Schaefer, B; Viveiros, A; Al-Zoairy, R; Blach, S; Brandon, S; Razavi, H; Dorn, L; Finkenstedt, A; Effenberger, M; Graziadei, I; Sarcletti, M; Tilg, H; Zoller, H: Disease Burden of Hepatitis C in the Austrian state of Tyrol – Epidemiological Data and Model Analysis to achieve Elimination by 2030
P33
Strebinger, G; Feldman, A; Denkmayr, L; Strasser, M; Ruhaltinger, S; Huber-Schönauer, U; Niederseer, D; Stechemesser, L; Zandanell, S; Paulweber, B; Datz, C; Aigner, E: Mortality is increased in NAFLD patients with homozygosity for PNPLA3 risk allele
P34
Mandorfer, M; Kozbial, K; Schwabl, P; Chromy, D; Scheiner, B; Paternostro, R; Stättermayer, AF; Munda, P; Ferlitsch, A; Trauner, M; Peck-Radosavljevic, M; Ferenci, P; Reiberger, T: Resolution of clinically significant portal hypertension after sustained virologic response to interferon-free regimens prevents hepatic decompensation
P35
Pfisterer, N; Fuchs, E; Mandorfer, M; Pachofszky, T; Bischof, M; Pulgram, T; Bucsics, T; Schwabl, P; Sandriesser, L; Scheiner, B; Gessl, I; Dolak, W; Ferlitsch, A; Schoeniger-Hekele, M; Trauner, M; Peck-Radosavljevic, M; Madl, C; Reiberger, T: The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites
P36
Staufer, K; Marculescu, R; Obermayer-Pietsch, B; Stift, J; Lackner, C; Trauner, M; Stauber, R: Enhanced liver fibrosis (ELF) score accurately detects advanced fibrosis in nonalcoholic fatty liver disease (NAFLD)
P37
Semmler, G; Scheiner, B; Schwabl, P; Bucsics, T; Paternostro, R; Trauner, M; Mandorfer, M; Ferlitsch, A; Reiberger, T: The impact of hepatic steatosis on portal hypertension
P38
Rainer, F; Horvath, A; Bashir, M; Leber, B; Schmerböck, B; Blesl, A; Groselj-Strele, A; Stauber, RE; Fickert, P; Stiegler, P; Stadlbauer, V: Störung der Kolonisationsresistenz bei Leberzirrhose: Assoziation mit Veillonella parvula
P39
Schwabl, P; Supper, P; Peck-Radosavljevic, M; Trauner, M; Reiberger, T: The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH
P40
Semmler, G; Stift, J; Scheiner, B; Paternostro, R; Schwabl, P; Pinter, M; Stättermayer, A; Trauner, M; Reiberger, T; Mandorfer, M: Limited diagnostic performance of controlled attenuation parameter for assessing hepatic steatosis in patients with advanced chronic liver disease and portal hypertension
P41
Mandorfer, M; Haider, L; Güngören, Z; Reiberger, T; Bastati, N; Hodge, JC; Chromy, D; Trauner, M; Herold, C; Peck-Radosavljeiv, M; Ba-Ssalamah, A: Gadoxetic acid enhanced MRI distinguishes advanced chronic liver disease patients with improving liver function after sustained virologic response and patients with persistent liver damage
P42
Riedl, F; Stättermayer, M; Pfisterer, N; Trauner, M; Mayer, A; Reiberger, T; Maieron, A: Project presentation: Outcome and survival of patients with acute variceal bleeding at the UK St. Pölten, a register
P43
Semmler, G; Stift, J; Walzel, C; Mandorfer, M; Schwarzer, R; Schwabl, P; Paternostro, R; Scheiner, B; Pinter, M; Stättermayer, A; Trauner, M; Peck-Radosavljevic, M; Ferlitsch, A; Reiberger, T: Transjugular liver biopsy performed by Hepatologists trained in hepatic venous pressure gradient measurements is safe and provides important diagnostic and prognostic information
P44
Kozbial, K; Al-Zoairy, R; Schaefer, B; Gschwantler, M; Stauber, R; Hametner, S; Maieron, A; Laferl, H; Strasser, M; Hayat-Khayyati, A; Datz, C; Kramer, L; Graziadei, I; Stättermayer, A; Beinhardt, S; Munda, P; Zoller, H; Holzmann, H; Trauner, M; Hofer, H; Ferenci, P: Retreatment of patients with chronic hepatitis C who failed interferon-free direct acting antiviral therapy
P45
Feldman, A; Denkmayr, L; Strasser, M; Ruhaltinger, S; Strebinger, G; Huber-Schönauer, U; Niederseer, D; Stechemesser, L; Zandanell, S; Paulweber, B; Datz, C; Aigner, E: Histological severity is related to cardiovascular events in lean but not in overweight and obese subjects with NAFLD
P46
Gschwantler, M; Gutic, E; Lang, T; Schütz, A; Schwanke, C; Schubert, R; Luhn, J; Haltmayer, H: Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C – data from an Austrian “real-life”-cohort
P47
Leber, B; Horvath, A; Schmerböck, B; Posch, A; Streit, A; Spindelböck, W; Stiegler, P; Stauber, RE; Stadlbauer, V: Direct acting anti-viral therapy improves neutrophil dysfunction in hepatitis C infection by ameliorating haemolysis
P48
Effenberger, M; Zoller, H; Tilg, H: Fulminant Liver Failure and Impaired hepatitis A virus clearance
P49
Strasser, M; Hondl, N; Wörz, A; Aigner, E: Pontine Myelinolyse als wahrscheinliche Nebenwirkung der antiviralen Therapie
P50
Steinacher, D; Traussnigg, S; Halilbasic, E; Paternostro, R; Stumptner, C; Zatloukal, K; Haslacher, H; Trauner, M: The influence of sampling time of liver tissue from biopsy to freezing on RNA quality assessed in the framework of the Austrian biobanking and biomolecular resources research infrastructure – BBMRI
P51
Viveiros, A; Schäfer, B; Tobiasch, M; Finkenstedt, A; Kremser, C; Plaikner, M; Henninger, B; Tilg, H; Zoller, H: Low splenic iron is characteristic of HFE-associated hemochromatosis
P52
Schmidbauer, C; Chromy, D; Schmidbauer, V; Bucsics, T; Schwabl, P; Mandorfer, M; Scheiner, B; Rieger, A; Holzmann, H; Trauner, M; Reiberger, T: Epidemiological trends of HBV and HDV coinfection among HIV+ patients
P53
Halilbasic, E; Zoller, H; Munda, P; Owens-Grillo, J; Malecha, ES; MacConell, L; Trauner, M: Durable Response in the Markers of Cholestasis Through 36 Months of Open-Label Extension with Obeticholic Acid in Austrian and German Patients with Primary Biliary Cholangitis
P54
Hametner, S; Weitersberger, M; Schöfl, R; Fritz, T; Maieron, A: Hepatitis C bei Suchtpatienten – Diagnose, Therapie und Nachbetreuung
P55
Bucsics, TA; Emich, M; Nackenhorst, M; Berger, E; Schwabl, P; Mandorfer, M; Scheiner, B; Ferlitsch, A; Reiberger, T; Trauner, M: Prevalence and Resistance Rates of Infections with Enterococci in Patients with Cirrhosis
P56
Steininger, L; Scheiner, B; Semmler, G; Schwabl, P; Bucsics, T; Paternostro, R; Ferlitsch, A; Trauner, M; Reiberger, T; Mandorfer, M: Controlled attenuation parameter (CAP®) does not predict hepatic decompensation in patients with compensated advanced chronic liver disease
P57
Chromy, D; Schwabl, P; Bucsics, T; Scheiner, B; Schmidbauer, C; Aichelburg, M; Ferenci, P; Trauner, M; Reiberger, T; Mandorfer, M: Impact of SVR to IFN-free DAA regimens on steatosis in HIV/HCV coinfected patients
P58
Paternostro, R; Heinisch, B; Reiberger, T; Mandorfer, M; Seeland, B; Schwarzer, R; Trauner, M; Peck-Radosavljevic, M; Ferlitsch, A: Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis
P59
Paternostro, R; Stättermayer, A; Trauner, M; Ferenci, P; Ferlitsch, A: Transient elastography, APRI and FIB-4 scores for staging of fibrosis and cirrhosis in Wilson disease
P60
Scheiner, B; Kirstein, M; Popp, S; Hucke, F; Bota, S; Rohr-Udilova, N; Reiberger, T; Müller, C; Trauner, M; Peck-Radosavljevic, M; Vogel, A; Sieghart, W; Pinter, M: Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma